Your session is about to expire
← Back to Search
Hemodialysis Device
Comparison of Conventional Dialysis and the Allient System
N/A
Waitlist Available
Led By Nathan W. Levin, MD
Research Sponsored by Renal Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
The purpose of the study to determine whether the level of inflammation may be decreased, the lifespan of red blood cells increased and the clearance of waste products in the blood improved through the use of the Allient System as compared to conventional hemodialysis.
Eligible Conditions
- Chronic Kidney Disease
- Kidney Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AExperimental Treatment1 Intervention
Subject will continue conventional hemodialysis therapy for one week ("no intervention" phase) and then swtich to the Allient system for two weeks ("active comparator" phase).
Find a Location
Who is running the clinical trial?
Renal Research InstituteLead Sponsor
34 Previous Clinical Trials
79,374 Total Patients Enrolled
Renal Solutions, Inc.Industry Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Nathan W. Levin, MDPrincipal InvestigatorRenal Research Institute
1 Previous Clinical Trials
30 Total Patients Enrolled
Peter Kotanko, MDStudy DirectorRenal Research Institute
12 Previous Clinical Trials
65,957 Total Patients Enrolled